Search Result

Isoforms Recommended:	EZH2

Results for "

EZH2

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (3) Androgen Receptor (3) Apoptosis (18) Autophagy (4) Bcl-2 Family (1) BCL6 (1) Caspase (1) CDK (1) Drug Derivative (2) Drug Metabolite (1) E1/E2/E3 Enzyme (1) E3 Ligase Ligand-Linker Conjugates (12) Epigenetic Reader Domain (1) Estrogen Receptor/ERR (3) Fluorescent Dye (1) HDAC (3) HIF/HIF Prolyl-Hydroxylase (2) Histamine Receptor (1) Histone Demethylase (2) Histone Methyltransferase (137) HSP (1) HyT (1) IAP (2) Influenza Virus (1) Isotope-Labeled Compounds (1) Keap1-Nrf2 (1) Ligands for Target Protein for PROTAC (5) mTOR (3) Necroptosis (1) Orthopoxvirus (4) PANoptosis (1) Parasite (1) PARP (4) PI3K (3) Potassium Channel (1) PROTAC Linkers (2) PROTACs (44) Pyroptosis (1) Reactive Oxygen Species (ROS) (1) Reference Standards (5) S-adenosylhomocysteine hydrolase (SAHH) (3) Sirtuin (1) Small Interfering RNA (siRNA) (3) Target Protein Ligand-Linker Conjugates (1) Thyroid Hormone Receptor (3) VSV (1) Wnt (1)
By Research Areas:	Cancer (144) Cardiovascular Disease (5) Endocrinology (2) Infection (6) Inflammation/Immunology (11) Metabolic Disease (5) Neurological Disease (3)
Click Chemistry:	Azide (3) Alkynes (1)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) siRNAs (3)

165

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

GMP Molecules

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-13803

Tazemetostat 85+ Cited Publications EPZ-6438; E-7438	Histone Methyltransferase Apoptosis	Cancer
Tazemetostat (EPZ-6438) is a potent, selective and orally available *EZH2* inhibitor. Tazemetostat inhibits the activity of human polycomb repressive complex 2 (PRC2)-containing wild-type EZH2 with a K_i value of 2.5 nM. Tazemetostat inhibits EZH2 with IC₅₀s of 11 and 16 nM in peptide assay and nucleosome assay, respectively. Tazemetostat inhibits rat EZH2 with an IC₅₀ of 4 nM. Tazemetostat also inhibits EZH1 with an IC₅₀ of 392 nM. Tazemetostat induces apoptosis and differentiation specifically in SMARCB1-deleted MRT cells .

HY-13500

GSK343 30+ Cited Publications	Histone Methyltransferase Autophagy	Cancer
GSK343, a chemical probe, is a highly potent and selective *EZH2* inhibitor with an IC₅₀ of 4 nM.

HY-145602

Tulmimetostat CPI-0209	Histone Methyltransferase	Cancer
Tulmimetostat (CPI-0209) is an orally active *EZH1/EZH2* inhibitor that targets and inhibits the *EZH2* enzyme.Tulmimetostat has antitumor activity and is used in a variety of solid tumor studies ^[2] .

HY-133129

MS1943 4 Publications Verification	HyT Histone Methyltransferase Apoptosis	Inflammation/Immunology Cancer
MS1943 is an orally active selective HyT degrader of *EZH2* that effectively reduces *EZH2* levels in cells. MS1943 has anticancer activity and exhibits cytotoxic effects in a variety of TNBC cells while sparing normal cells. In addition, MS1943 maintains high potency (IC₅₀=120 nM) in inhibiting EZH2 methyltransferase activity and is highly selective for *EZH2. (Structure Note: RED, EZH2* ligand (HY-148458); Blue, Hyt (HY-W001578)) .

HY-N5024

Gambogenic acid 2 Publications Verification	Histone Methyltransferase	Cancer
Gambogenic acid is an active ingredient that can be isolated from gamboge. Gambogenic acid acts as an effective inhibitor of *EZH2, specifically and covalently binds to Cys668 within the EZH2-SET* domain, and induces EZH2 ubiquitination. Gambogenic acid can be used for the research of cancer ^[2].

HY-147525

*PROTAC EZH2* Degrader-1** 1 Publications Verification	PROTACs Histone Methyltransferase	Cancer
PROTAC EZH2 Degrader-1 (Compound 150d), a potent PROTAC EZH2 Degrader, exerts inhibitory effect on EZH2 methyltransferase activity with the IC₅₀ of 2.7 nM. EZH2 plays an important role in many tumorigenesis and development processes .

HY-148333

MS177 3 Publications Verification	PROTACs Histone Methyltransferase Apoptosis	Cancer
MS177 is an effective and fast-acting *EZH2* degrader. MS177 is a PROTAC that consists of a CRBN ligand, linker, and a potent enzymatic EZH2 inhibitor C24 (C24 IC₅₀): 12 nM). MS177 effectively depletes both canonical EZH2-PRC2 and noncanonical EZH2-cMyc complexes. MS177 induces leukaemia cell growth inhibition, apoptosis and cell cycle progression arrest .

HY-153191

EZH2-IN-15 1 Publications Verification	Histone Methyltransferase	Cancer
EZH2-IN-15 is a *EZH2* inhibitor. EZH2-IN-15 has anti-tumor activity, and can be used for research of H3K27me3-dependent tumors .

HY-148458

EZH2-IN-14	Histone Methyltransferase	Cancer
EZH2-IN-14 is a selective *EZH2* (Histone Methyltransferase) inhibitor with an IC₅₀ of 12 nM. EZH2-IN-14 inhibits the methyltransferase activity of EZH2/PRC2 (that is, reducing H3K27me3). EZH2-IN-14 shows >200-fold selective for EZH2 over the highly homologous H3K27 methyltransferase EZH1 .

HY-147091

Tazemetostat de(methyl morpholine)-COOH	Ligands for Target Protein for PROTAC	Cancer
Tazemetostat de(methyl morpholine)-COOH (compound 7) is a ligand for the PROTAC target protein *EZH2, which can be used to synthesis of EZH2* degraders (PROTACs). *EZH2* degraders have potent cell viability inhibition in diffuse large B-cell lymphoma (DLBCL) and other subtypes of lymphoma .

HY-157164

*PROTAC EZH2* Degrader-2** 1 Publications Verification	PROTACs Histone Methyltransferase Apoptosis	Cancer
PROTAC EZH2 Degrader-2 is a PROTAC *EZH2* inhibitor. PROTAC EZH2 Degrader-2 degrades *EZH2* in SU-DHL-6 cells in a dose-dependent manner. PROTAC EZH2 Degrader-2 induces apoptosis and reduces mitochondrial membrane potential in SU-DHL-6 cells. PROTAC EZH2 Degrader-2 has anti-cancer and anti-proliferative activity .

HY-13803R

Tazemetostat (Standard) EPZ-6438 (Standard); E-7438 (Standard)	Reference Standards Histone Methyltransferase Apoptosis	Cancer
Tazemetostat (Standard) is the analytical standard of Tazemetostat. This product is intended for research and analytical applications. Tazemetostat (EPZ-6438) is a potent, selective and orally available *EZH2* inhibitor. Tazemetostat inhibits the activity of human polycomb repressive complex 2 (PRC2)-containing wild-type EZH2 with a K_i value of 2.5 nM. Tazemetostat inhibits EZH2 with IC₅₀s of 11 and 16 nM in peptide assay and nucleosome assay, respectively. Tazemetostat inhibits rat EZH2 with an IC₅₀ of 4 nM. Tazemetostat also inhibits EZH1 with an IC₅₀ of 392 nM. Tazemetostat induces apoptosis and differentiation specifically in SMARCB1-deleted MRT cells .

HY-103682

PF-06726304 1 Publications Verification	Histone Methyltransferase	Cancer
PF-06726304 is a potent and selective *EZH2* inhibitor. PF-06726304 inhibits wild-type and Y641N mutant EZH2 with K_is of 0.7 and 3.0 nM, respectively. PF-06726304 displays robust antitumor growth activity .

HY-A0298

EZH2-IN-2	Histone Methyltransferase	Cancer
EZH2-IN-2 (Example 69) is a *EZH2* inhibitor with an IC₅₀ and a TR-FRET IC₅₀ of 64 nM and 20 nM. EZH2-IN-2 can be used for the research of cancer or precancerous condition related to EZH2 activity .

HY-15573

EI1 2 Publications Verification KB-145943	Histone Methyltransferase Apoptosis	Cancer
EI1 (KB-145943) is a potent and selective EZH2* inhibitor* with IC₅₀ of 15 nM and 13 nM for EZH2 (WT) and EZH2 (Y641F), respectively.

HY-101508

GNA002	Histone Methyltransferase	Cancer
GNA002 is a highly potent, specific and covalent *EZH2* (Enhancer of zeste homolog 2) inhibitor with an IC₅₀ of 1.1 μM. GNA002 can specifically and covalently bind to Cys668 within the EZH2-SET domain, triggering EZH2 degradation through COOH terminus of Hsp70-interacting protein (CHIP)-mediated ubiquitination. GNA002 efficiently reduces EZH2-mediated H3K27 trimethylation, reactivates polycomb repressor complex 2 (PRC2)-silenced tumor suppressor genes .

HY-148334

MS8815	PROTACs Histone Methyltransferase	Cancer
MS8815 is a selective enhancer of zeste homolog 2 (EZH2) PROTAC degrader. MS8815 has inhibition activity for EZH2 with an IC₅₀ value of 8.6 nM. MS8815 can be used for the research of triple-negative breast cancer (TNBC) .

HY-RS04619

EZH2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
EZH2 Human Pre-designed siRNA Set A contains three designed siRNAs for EZH2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

EZH2 Human Pre-designed siRNA Set A EZH2 Human Pre-designed siRNA Set A

HY-116804

ZLD1039	Histone Methyltransferase	Cancer
ZLD1039 is a potent, highly selective, and orally bioavailable *EZH2* inhibitor. ZLD1039 shows potent and concentration-dependent inhibition of PRC2 enzymatic activity against EZH2 wild-type as well as Y641F, and A677G mutant enzymes with IC₅₀ values of 5.6, 15, and 4.0 nM, respectively. ZLD1039 inhibits breast tumor growth and metastasis .

HY-100846

JQEZ5 3 Publications Verification	Histone Methyltransferase	Cancer
JQEZ5 is a potent and selective EZH2 lysine methyltransferase inhibitor. JQEZ5 SAM-competitively inhibits polycomb repressive complex 2 (PRC2) with an IC₅₀ of 80 nM. JQEZ5 has anti-tumor effects .

HY-144330

TDI-6118	Histone Methyltransferase	Cancer
TDI-6118 (Compound 5) is a potent brain-penetrant inhibitor of *EZH2. EZH2-IN-12* has the potential for the research of central nervous system malignancies .

HY-12856

GSK503 5+ Cited Publications	Histone Methyltransferase	Cancer
GSK503 is a potent and specific inhibitor of *EZH2* methyltransferase with K_i ^app values of 3 to 27 nM.

HY-168131

*PROTAC EZH2* Degrader-3**	PROTACs Histone Methyltransferase Apoptosis	Cancer
PROTAC EZH2 Degrader-3 (compound ZJ-20) is a *EZH2* PROTAC degrader. PROTAC EZH2 Degrader-3 (5 μM, 24 h) not only potently inhibits the expression of EZH2 protein, but also had a strong inhibits effect on the expression levels of other subunits of PRC2 as well as H3k27me3 protein. PROTAC EZH2 Degrader-3 shows anti-proliferative activity and blocks the cell cycle in the G0-G1 phase and induces cell apoptosis((Blue: cereblon ligand Pomalidomide (HY-10984), Black: linker HY-W361751；Pink: EZH2 inhibitor Tazemetostat (HY-13803)) .

HY-RS04620

Ezh2 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Ezh2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Ezh2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Ezh2 Mouse Pre-designed siRNA Set A Ezh2 Mouse Pre-designed siRNA Set A

HY-176165

*CDK9/EZH2-IN-1*	CDK Histone Methyltransferase	Cancer
CDK9/EZH2-IN-1 (Compound D16) is a *CDK9/EZH2* dual-target inhibitor (IC₅₀: 83.9/108.6 nM). CDK9/EZH2-IN-1 induces apoptosis and DNA double-strand breaks (DSBs). CDK9/EZH2-IN-1 inhibits the proliferation activity of MKN45, MDA-MB-453 and SW620 cancer cells (IC₅₀ values are 136.3, 171.3 and 315.7 nM, respectively) .

HY-141566

EZH2-IN-5	Histone Methyltransferase	Cancer
EZH2-IN-5 is a potent *EZH2* inhibitor with IC₅₀ values of 1.52 nM and 4.07 nM for wild-type and mutant Tyr641 EZH2, respectively .

HY-136188

UNC2399	Histone Methyltransferase	Cancer
UNC2399, a biotinylated UNC1999, is a selective *EZH2* inhibitor, maintaining high in vitro potency for EZH2, with an IC₅₀ of 17 nM ^[2].

HY-149726

EZH2-IN-17	Histone Methyltransferase	Cancer
EZH2-IN-17 (compound 28) is a potent and orally active *EZH2* inhibitor with an IC₅₀ value of 0.95 nM. EZH2-IN-17 exhibits high anti-proliferation activity against different lymphoma cell lines including WSU-DLCL2, Pfeiffer and Karpas-422 (IC50 values of 2.36 nM, 1.73 nM, and 1.82 nM, respectively) .

HY-D2274

EZH2-AF647	Fluorescent Dye	Others
EZH2-AF647 is a fluorescent probe derived from UNC2239 that improves receptor TR-FRET properties by using Alexa 647 dye .

HY-132885

*PARP/EZH2-IN-1*	PARP Histone Methyltransferase	Cancer
PARP/EZH2-IN-1 is a first-in-class dual PARP-1/EZH2 inhibitor with IC₅₀ values of 6.87 nM and 36.51 nM, respectively. PARP/EZH2-IN-1 induces autophagy in cancer cells and shows potent antiproliferative activity in BRCA wild-type triple-negative breast cancer cells .

HY-174372

EZH2-IN-23	Histone Methyltransferase	Cancer
EZH2-IN-23 (Compound 25) is an *EZH2* inhibitor that exhibits potent enzymatic inhibition of the PRC2 complex (EZH2, EED, SUZ12, AEBP2, RbAp48) with a biochemical IC₅₀ of 0.8 nM. EZH2-IN-23 inhibits H3K27 trimethylation in cellular assays, showing an IC₅₀ of 40 nM. EZH2-IN-23 displays good rat PKproperties with 100 % oral bioavailability.

HY-147230

EZH2-IN-13	Histone Methyltransferase	Cancer
EZH2-IN-13 is a potent *EZH2* inhibitor, for details please refer to compound 73 in patent WO2017139404. EZH2-IN-13 can be used to study cancers or precancerous lesions associated with EZH2 activity .

HY-P2266

SAH-EZH2	Histone Methyltransferase	Cancer
SAH-EZH2, a stable EZH2 α-helical peptide, is an EZH2/EED interaction inhibitor. SAH-EZH2 targets native embryonic ectoderm development (EED), disturbs its interactions with EZH1 and EZH2, and selectively decreases trimethylation of H3K27 .

HY-179386

*PARP1/EZH2-IN-1*	PARP Histone Methyltransferase Apoptosis Pyroptosis Necroptosis Reactive Oxygen Species (ROS) PANoptosis	Cancer
PARP1/EZH2-IN-1 is a selective PARP1 and *EZH2* dual inhibitor. PARP1/EZH2-IN-1 has IC₅₀s of 28 nM, 414 nM and 74 nM for PARP1, *PARP2* and *EZH2, respectively. PARP1/EZH2-IN-1* inhibits the proliferation and migration of TNBC cells (triple-negative breast Cancer cells). PARP1/EZH2-IN-1 induces PANoptosis (Apoptosis, Pyroptosis and Necroptosis), increases the level of reactive oxygen species (ROS), and activates related inflammatory pathways. PARP1/EZH2-IN-1 can be used in triple-negative breast cancer research .

HY-156292

*IHMT-EZH2-426*	Histone Methyltransferase	Cancer
IHMT-EZH2-426 (compound 38) is an effective covalent *EZH2* degrader, with IC₅₀ values of 1.3 nM, 1.2 nM, and 1.7-3.5 nM for EZH2 wild type, EZH2-A687V, and EZH2-Y641F/Y641N/Y641S, respectively. IHMT-EZH2-426 reduces H3K27me3 and EZH2 levels and shows effective anti-proliferative effects in B-cell lymphoma and TNBC cell lines.

HY-144882

(R)-HH2853	Histone Methyltransferase	Inflammation/Immunology Cancer
(R)-HH2853 is a mutant EZH2 inhibitor with an IC₅₀ of <100 nM for *EZH2-Y641F*. (R)-HH2853 can be used for cancer and autoimmune diseases (WO2018045971A1; compound 201) .

HY-16986B

EPZ011989 hydrochloride 3 Publications Verification	Histone Methyltransferase	Cancer
EPZ011989 hydrochloride is a potent and orally active Zeste Homolog 2 (EZH2) inhibitor, with a K_i value of <3 nM. EPZ011989 shows anti-tumor activity. EPZ011989 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups .

HY-122936

Tanshindiol C	Histone Methyltransferase Keap1-Nrf2 Sirtuin	Cardiovascular Disease Cancer
Tanshindiol C is a S-adenosylmethionine-competitive *EZH2* (Histone Methyltransferase) inhibitor with an IC₅₀ of 0.55 μM for inhibiting the methyltransferase activity. Tanshindiol C is also an activator of both *Nrf2* and Sirtuin 1 (Sirt1) in macrophages. Tanshindiol C possesses anti-cancer activity, and can be used for atherosclerosis research ^[2].

HY-149463

EZH2-IN-16	Histone Methyltransferase	Cancer
EZH2-IN-16 (Compound 24) is an inhibitor for histone methyltransferase (EZH2). EZH2-IN-16 inhibits EZH2 and EZH2 Y641F, with IC₅₀ of 37.6 and 79.1 nM. EZH2-IN-16 inhibits proliferation of WSU-DLCL2, with GI₅₀ of 0.2 μM .

HY-RS04621

Ezh2 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Ezh2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Ezh2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Ezh2 Rat Pre-designed siRNA Set A Ezh2 Rat Pre-designed siRNA Set A

HY-161083

*PARP/EZH2-IN-2*	PARP Histone Methyltransferase	Cancer
PARP/EZH2-IN-2 (compound 12e) is a dual target PARP1 and *EZH2* inhibitor, with IC₅₀ values of 6.89 and 27.34 nM, respectively. PARP/EZH2-IN-2 shows anticancer activity, with no toxicity to normal cells. PARP/EZH2-IN-2 achieves synthetic lethality indirectly by inhibiting EZH2 to increase the sensitivity to PARP1, and induces cell death by regulating excessive autophagy .

HY-181324

*PROTAC EZH2* Degrader-23**	PROTACs Histone Methyltransferase	Cancer
PROTAC EZH2 Degrader-23 (compound 8) is a PROTAC protein degrader targeting *EZH2* with a target IC₅₀ of 30.00 nM. PROTAC EZH2 Degrader-23 inhibits *EZH2* methyltransferase activity via interaction with the *EZH2* SET domain .

HY-181333

*PROTAC EZH2* Degrader-38**	PROTACs Histone Methyltransferase	Others
PROTAC EZH2 Degrader-38 (Compound 17) is a *EZH2* PROTAC degrader with an IC₅₀ of 165.00 nM. PROTAC EZH2 Degrader-38 functionally inhibits the methyltransferase activity of *EZH2* and competitively binds to the SAM-binding pocket of the *EZH2* SET domain .

HY-181393

EZH2 ligand-3	Ligands for Target Protein for PROTAC Histone Methyltransferase	Cancer
EZH2 ligand-3, a *EZH2* ligand, is a PROTAC target protein ligand (Ligand for Target Protein for PROTAC). EZH2 ligand-3 can be used for the synthesis of PROTAC EZH2 Degrader-35 (HY-181392) .

HY-181325

*PROTAC EZH2* Degrader-24**	PROTACs Histone Methyltransferase	Cancer
PROTAC EZH2 Degrader-24 (compound 9) is an *EZH2*-targeting PROTAC with *EZH2* methyltransferase inhibitory activity .

HY-181332

*PROTAC EZH2* Degrader-37**	PROTACs Histone Methyltransferase	Cancer
PROTAC EZH2 Degrader-37 (compound 16) is a PROTAC protein degrader targeting *EZH2* with a target IC₅₀ of 144 nM. PROTAC EZH2 Degrader-37 is applicable to lymphoma-related research .

HY-181331

*PROTAC EZH2* Degrader-27**	PROTACs Histone Methyltransferase	Others
PROTAC EZH2 Degrader-27 is a *EZH2* PROTAC inhibitor with an IC₅₀ of 4.00 nM against *EZH2. PROTAC EZH2* Degrader-27 inhibits methyltransferase activity by interacting with the SET domain of *EZH2* .

HY-181334

*PROTAC EZH2* Degrader-39**	PROTACs Histone Methyltransferase	Cancer
PROTAC EZH2 Degrader-39 (compound 18) is a PROTAC protein degrader targeting *EZH2* with a target IC₅₀ of 61.00 nM. PROTAC EZH2 Degrader-39 functionally inhibits *EZH2* methyltransferase activity .

HY-181327

*PROTAC EZH2* Degrader-26**	PROTACs Histone Methyltransferase	Others
PROTAC EZH2 Degrader-26 (compound 11) is an *EZH2* degrader developed based on PROTAC technology. PROTAC EZH2 Degrader-26 has an IC₅₀ of 5.80 nM against *EZH2. PROTAC EZH2* Degrader-26 exhibits micromolar-level enzyme inhibitory activity against *EZH1, with an EZH*1 IC₅₀ of 0.06 μM .

HY-181309

*PROTAC EZH2* Degrader-15**	PROTACs Histone Methyltransferase	Cancer
PROTAC EZH2 Degrader-15 (compound 5) is an *EZH2*-targeting PROTAC. PROTAC EZH2 Degrader-15 functionally inhibits *EZH2* methyltransferase activity .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N5024

Gambogenic acid 2 Publications Verification	Classification of Application Fields Ketones, Aldehydes, Acids Guttiferae Phenols Polyphenols Plants Garcinia hanburyi Hook. f. Disease Research Fields Cancer Source Classification	Histone Methyltransferase
Gambogenic acid is an active ingredient that can be isolated from gamboge. Gambogenic acid acts as an effective inhibitor of *EZH2, specifically and covalently binds to Cys668 within the EZH2-SET* domain, and induces EZH2 ubiquitination. Gambogenic acid can be used for the research of cancer ^[2].

HY-122936

Tanshindiol C	Terpenoids Labiatae Samanea saman (Jacq.) Merr. Diterpenoids Plants	Histone Methyltransferase Keap1-Nrf2 Sirtuin
Tanshindiol C is a S-adenosylmethionine-competitive *EZH2* (Histone Methyltransferase) inhibitor with an IC₅₀ of 0.55 μM for inhibiting the methyltransferase activity. Tanshindiol C is also an activator of both *Nrf2* and Sirtuin 1 (Sirt1) in macrophages. Tanshindiol C possesses anti-cancer activity, and can be used for atherosclerosis research ^[2].

HY-122108

Ilicicolin A LL-Z 1272-alpha	Microorganisms Phenols Polyphenols Source Classification	Apoptosis
Ilicicolin A is a potent anticancer agent. Ilicicolin A induces apoptosis. Ilicicolin A inhibits cell growth and colony formation. Ilicicolin A shows antitumor activity. Ilicicolin A has the potential for the research of prostate cancer .

Cat. No.	Product Name	Chemical Structure

HY-W011927S

4,4'-Sulfonyldiphenol-d8

1 Publications Verification

4,4'-Sulfonyldiphenol-d₈ (Bisphenol S (4,4'-Sulfonyldiphenol)-d₈) is the deuterium labeled 4,4'-Sulfonyldiphenol (HY-W011927).4,4'-Sulfonyldiphenol (Bisphenol S; Bis(4-hydroxyphenyl) sulfone), a substitute for Bisphenol A (HY-18260), is widely used in industrial and consumer products. 4,4'-Sulfonyldiphenol is an estrogen receptor (ER) agonist and can competitively bind to thyroid hormone receptors (TR) with IC₅₀ values for TRα and TRβ are 2650 μM and 2294 μM respectively, thereby affecting breast development and reducing the expression of androgen receptor (AR) in fetal testes. 4,4'-Sulfonyldiphenol promotes the progression of glioblastoma by upregulating the EZH2 mediated PI3K/AKT/mTOR pathway. Under chronic exposure, 4,4'-Sulfonyldiphenol can cause significant lipid deposition and dyslipidemia in the mouse liver by upregulating JunB and Atf3, and has a role in causing obesity at low doses. 4,4'-Sulfonyldiphenol induces intestinal inflammation by altering the intestinal microbiome. 4,4'-Sulfonyldiphenol accelerates the progression of atherosclerosis in zebrafish embryo larvae.

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-12186G

3-Deazaneplanocin A hydrochloride DZNep hydrochloride; NSC 617989 hydrochloride; 3-Deazaneplanocin hydrochloride	Histone Methyltransferase Orthopoxvirus	Infection Cancer
3-Deazaneplanocin A (DZNep) hydrochloride (GMP) is 3-Deazaneplanocin A hydrochloride (HY-12186) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. 3-Deazaneplanocin A hydrochloride is a potent histone methyltransferase EZH2 inhibitor ^[2].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks